Surefire Medical, Inc.’s New Precision Infusion System For Embolization Procedures Receives CE Mark Approval

WESTMINSTER, Colo.--(BUSINESS WIRE)--Surefire Medical, Inc. today announced that the company’s new Precision targeted delivery infusion system, for direct-to-tumor embolization procedures, has received the CE Mark from European regulators. Surefire infusion systems are today used primarily in treating inoperable liver cancers, although clinical trials are under way for additional medical conditions.

“This product with its improved trackability will enable significant growth opportunities for Surefire Medical in the large worldwide primary liver cancer market”

“This product with its improved trackability will enable significant growth opportunities for Surefire Medical in the large worldwide primary liver cancer market,” said President and CEO James E. Chomas. “The rapidly growing body of clinical evidence indicates greater drug penetration into tumors with the unique Surefire infusion systems, which addresses a clear need in a treatment of primary liver cancer that can bridge patients to a liver transplant or extend their life by suppressing tumor growth.”

The value of the primary hepatocellular cancer (HCC) market is set to grow by 172% by 2019, according to independent analyst firm Datamonitor Healthcare.

Liver cancer is the third most common cause of cancer deaths worldwide, with 2.2 million cases. In the U.S. the liver cancer death rate doubled between 1981 and 2010, from eight to 16.3 deaths per 100,000 people, according to statistics released recently by the Centers for Disease Control and Prevention (CDC).

HCC is the most common form of liver cancer, accounting for 83% of total liver cancer incidence. With approximately 80% of liver cancers being inoperable, today most patients are treated with a minimally invasive embolization procedure performed by an interventional radiologist.

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip, which collapses in forward flow and dynamically expands to the vessel wall in reverse flow. Recent clinical studies suggest that the resulting pressure gradient changes preferentially shunt particles into the tumor compartment, temporarily increasing uptake by the tumor but not normal liver tissue. For clinical trial results, and more information please visit www.surefiremedical.com.